Feb 4, 2026
1003(a)(i) - Equity below $2 million and years of losses
NYSE American
OPEN
On April 22, 2026, the exchange accepted VolitionRx's compliance plan after previously issuing a non-compliance notice on February 6, 2026, under Section 1003(a)(i) for failing to maintain at least $2.0 million in stockholders' equity alongside a history of net losses. The company remains listed and has been granted until August 6, 2027, to regain compliance with the continued listing standards. Filed At: 2026-04-23
Feb 4, 2026
1003(a)(ii) - Equity below $4 million and years of losses
NYSE American
OPEN
On April 22, 2026, the exchange accepted VolitionRx's compliance plan after issuing an initial non-compliance notice on February 6, 2026, regarding Section 1003(a)(ii) for failing to maintain the required $4.0 million in stockholders' equity. The company has been granted an extension through August 6, 2027, to regain compliance while remaining listed subject to periodic progress reviews. Filed At: 2026-04-23
Feb 4, 2026
1003(a)(iii) - Equity below $6 million and years of losses
NYSE American
OPEN
After receiving a non-compliance notice on February 6, 2026, for failing to meet the $6.0 million stockholders' equity requirement under Section 1003(a)(iii) due to five consecutive years of net losses, VolitionRx had its compliance plan accepted on April 22, 2026. The company remains listed and has been granted until August 6, 2027, to regain compliance with the exchange's continued listing standards. Filed At: 2026-04-23
Feb 5, 2026
1003(a)(iii) - Equity below $6 million and years of losses
NYSE American
RESOLVED
Following an initial non-compliance notice on February 6, 2026, regarding Section 1003(a)(iii) for having stockholders' equity below $6.0 million with a history of net losses, the exchange accepted VolitionRx’s compliance plan on April 22, 2026. The company's stock continues to trade subject to periodic review, with a deadline of August 6, 2027, to fully regain compliance. Filed At: 2026-04-23
Feb 5, 2026
1003(a)(i) - Equity below $2 million and years of losses
NYSE American
RESOLVED
After receiving an initial non-compliance notice on February 6, 2026, regarding Section 1003(a)(i) stockholders' equity requirements, VolitionRx had its compliance plan accepted on April 22, 2026. The company has been granted an extension until August 6, 2027, to regain compliance while remaining listed and subject to periodic progress reviews. Filed At: 2026-04-23
Feb 5, 2026
1003(a)(ii) - Equity below $4 million and years of losses
NYSE American
RESOLVED
Following a February 6, 2026 notice of non-compliance under Section 1003(a)(ii) for failing to maintain $4.0 million in stockholders' equity with losses in three of its last four fiscal years, the NYSE American accepted VolitionRx's compliance plan on April 22, 2026. The company was granted an extension through August 6, 2027, to regain compliance with the listing standards while remaining listed and subject to periodic exchange reviews (Filed At: 2026-04-23).
